Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

"While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer's disease, the extensive body of ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. | Vanda Pharmaceuticals’ ...

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in ...

FAT jabs could harm mum and baby if taken too close to pregnancy, a study suggests. Women who used the GLP-1 injections, such ...

Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main ​goal in late-stage trials ...

Scientists are uncovering how GLP-1 drugs like Ozempic and Wegovy act on brain regions that control hunger, nausea, pleasure-based eating, and thirst. These discoveries may help create treatments that ...

In the first quarter of 2018, there were less than five postpartum GLP-1 prescriptions, but by the second quarter of 2022, the number rose to 34 per 10,000 and sharply increased to 173 per 10,000 in ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

Stock futures are moving higher this morning after experiencing significant volatility last week amid growing concerns about the possibility of an AI bubble. Stocks rose on Friday after a Federal ...

The results show the treatment's potential to mitigate GLP-1 induced nausea and vomiting, which are key factors for those who stop using weight-loss drugs, Vanda Chief Executive Mihael Polymeropoulos ...